Hamidieh Amir, Kargar Mona, Jahani Mohammad, Alimoghaddam Kamran, Bahar Babak, Mousavi Seyed Asadollah, Iravani Masoud, Jalali Arash, Jalili Mahdi, Ghavamzadeh Ardeshir
Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
J Pediatr Hematol Oncol. 2012 Mar;34(2):101-7. doi: 10.1097/MPH.0b013e31824435a1.
The most widely accepted conditioning regimen to allogeneic hematopoietic stem cell transplantation consists of total body irradiation, especially in patients affected by acute lymphoblastic leukemia (ALL). In this retrospective study, we report our experience on hematopoietic stem cell transplantation in 44 pediatric patients with acute lymphoblastic leukemia using a non-radiation-based conditioning regimen (busulfan/cyclophosphamide). Median age at transplantation was 12.5 years (range, 4 to 14 y). 39 out of 44 patients received transplants in complete remission. At a median follow-up of 390 days, the probabilities of 3-year disease-free survival and overall survival were 50% and 68%, respectively. Disease status of hematopoietic stem cell transplantation was the only significant variable affecting the overall survival. Acute and chronic graft-versus-host disease occurred in 23 (64%) and 12(18%) patients, respectively. Relapse was significantly higher among patients transplanted in advanced disease status. The results of the study indicate that non-radiation-based preparative regimens can be used in pediatric patients with ALL. However, well-designed comparative trials are needed to better clarify the difference between radiation and non-radiation-based conditioning regimens in pediatric ALL.
异基因造血干细胞移植中最广泛接受的预处理方案包括全身照射,尤其是在急性淋巴细胞白血病(ALL)患者中。在这项回顾性研究中,我们报告了44例使用非放疗预处理方案(白消安/环磷酰胺)的急性淋巴细胞白血病儿科患者进行造血干细胞移植的经验。移植时的中位年龄为12.5岁(范围4至14岁)。44例患者中有39例在完全缓解期接受移植。中位随访390天时,3年无病生存率和总生存率分别为50%和68%。造血干细胞移植时的疾病状态是影响总生存的唯一显著变量。急性和慢性移植物抗宿主病分别发生在23例(64%)和12例(18%)患者中。疾病进展期移植的患者复发率显著更高。研究结果表明,非放疗预处理方案可用于ALL儿科患者。然而,需要设计良好的对照试验来更好地阐明放疗和非放疗预处理方案在儿科ALL中的差异。